Reporter brief
A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The study results are not reported in the provided abstract, so no conclusions about fisetin's efficacy can be drawn
- A sample size of 40 as a Phase II pilot study provides limited statistical power to detect meaningful effects
- The short dosing strategy and specific participant selection (smokers and never-smokers) mean findings may not generalize to all older adults
Study design and sample
Rct; Human.
Older adults aged 60 years and older, including individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers
- Design
- Rct
- Sample
- 40
- Journal
- Cedars-Sinai Medical Center
- Published
- Oct 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.